Literature DB >> 3943757

Radiation therapy alone in the treatment of carcinoma of the uterine cervix: a 20-year experience.

C A Perez, H M Camel, R R Kuske, M S Kao, A Galakatos, M A Hederman, W E Powers.   

Abstract

A retrospective analysis is reported on the results of irradiation alone in the treatment of 970 patients with histologically proven invasive carcinoma of the uterine cervix. The development of the radiation therapy techniques, survival, pelvic tumor control, and major sequelae of therapy are described in detail. The tumor-free 5-year survival rate was 100% in 29 patients with stage IA, 85% in 312 cases with stage IB, 70% in 98 patients with stage IIA, 68% in 276 patients with stage IIB, 45% in 237 stage III cases, and one survivor in 18 stage IV patients. No pelvic recurrences or distant metastases were observed in stage IA patients. In stage IB the overall incidence of pelvic recurrences was 7.3%, in stages IIA and IIB 14%, and in stage III 37%. Distant metastases were noted in 13% of the patients with stage IB, 22% of those with stages IIA and IIB, and 32% of patients with stage III tumors. Higher doses of irradiation delivered with intracavitary insertions and extenal beam were correlated with a lower incidence of pelvic recurrences in stages IIA, IIB, and III. However, doses to point A over 7000 cGy did not improve pelvic tumor control in stage IB. Grade 2 treatment sequelae were observed in about 10% of all patients and grade 3 complications in approximately 4% of the patients with stage I and 8% in those with more advanced tumors (IIA and beyond). The need is emphasized to carefully evaluate the dosimetric aspects of new techniques, including phantom studies before they are applied to patients. A close integration of external and intracavitary irradiation will result in better tumor control and fewer complications.

Entities:  

Mesh:

Year:  1986        PMID: 3943757     DOI: 10.1016/0090-8258(86)90216-7

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  13 in total

Review 1.  A review of recent developments in image-guided radiation therapy in cervix cancer.

Authors:  Azmat H Sadozye; Nicholas Reed
Journal:  Curr Oncol Rep       Date:  2012-12       Impact factor: 5.075

2.  Radiation therapy with chemotherapy for patients with cervical cancer and supraclavicular lymph node involvement.

Authors:  Seok Ho Lee; Seung Heon Lee; Kyu Chan Lee; Kwang Beom Lee; Jin Woo Shin; Chan Yong Park; Sun Jin Sym; Jun-Ho Lee
Journal:  J Gynecol Oncol       Date:  2012-07-02       Impact factor: 4.401

3.  A phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix--a Gynecologic Oncology Group Study.

Authors:  S C Plaxe; J A Blessing; J A Lucci; J A Hurteau
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

4.  Oncostatin M treatment increases the responsiveness toward cisplatin-based chemoradiotherapy in cervical cancer cells in a STAT3-dependent manner.

Authors:  Russalina Stroeder; Barbara Walch-Rückheim; Jil Fischbach; Ingolf Juhasz-Böss; Christian Rübe; Erich-Franz Solomayer; Sigrun Smola
Journal:  Oncol Lett       Date:  2018-06-18       Impact factor: 2.967

5.  The Diversity of Vaginal Microbiota Predicts Neoadjuvant Chemotherapy Responsiveness in Locally Advanced Cervical Cancer.

Authors:  Zizhuo Wang; Rourou Xiao; Jia Huang; Xu Qin; Dianxing Hu; Ensong Guo; Chen Liu; Funian Lu; Lixin You; Chaoyang Sun; Gang Chen
Journal:  Microb Ecol       Date:  2021-08-17       Impact factor: 4.552

6.  Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.

Authors:  Israel Zighelboim; Jason D Wright; Feng Gao; Ashley S Case; L Stewart Massad; David G Mutch; Matthew A Powell; Premal H Thaker; Eric L Eisenhauer; David E Cohn; Fidel A Valea; Angeles Alvarez Secord; Lynne T Lippmann; Farrokh Dehdashti; Janet S Rader
Journal:  Gynecol Oncol       Date:  2013-04-13       Impact factor: 5.482

7.  Severe metabolic acidosis and hypokalemia in a patient with enterovesical fistula.

Authors:  Kazutaka Murakami; Makoto Tomita; Nahoko Kawamura; Midori Hasegawa; Kunihiro Nabeshima; Yoshiyuki Hiki; Satoshi Sugiyama
Journal:  Clin Exp Nephrol       Date:  2007-09-28       Impact factor: 2.801

8.  Radiotherapy versus concurrent 5-day cisplatin and radiotherapy in locally advanced cervical carcinoma. Long-term results of a phase III randomized trial.

Authors:  Viorica Nagy; Ovidiu Coza; Claudia Ordeanu; Alexandru Trăilă; Alin Rancea; Nicolae Todor; Nicolae Ghilezan
Journal:  Strahlenther Onkol       Date:  2009-03-28       Impact factor: 3.621

9.  Interobserver variation in rectal and bladder doses in orthogonal film-based treatment planning of cancer of the uterine cervix.

Authors:  P Raghukumar; K Raghu Ram Nair; B Saju; G Zhenia; K T Divya; V S Shaiju; V Padmanabhan
Journal:  J Med Phys       Date:  2008-10

10.  Dosimetric evaluation of rectum and bladder using image-based CT planning and orthogonal radiographs with ICRU 38 recommendations in intracavitary brachytherapy.

Authors:  Swamidas V Jamema; Sherly Saju; Umesh Mahantshetty; S Pallad; D D Deshpande; S K Shrivastava; K A Dinshaw
Journal:  J Med Phys       Date:  2008-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.